Journal of molecular medicine (Berlin, Germany)HumansFemaleBreast NeoplasmsTrastuzumabCitric Acid Cycle
Targeted metabolomics reveals tricarboxylic acid cycle-related metabolites serve as predictive biomarkers for trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer.
Ting Yang, Bangbang Wei, Min Wang, Yu Wang, Yiwei Cao, Debang Li, Hongyan Song, Juan Wei, Xinxin Si
Published: 202510.1007/s00109-025-02603-3
Abstract
Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), has been proven to be effective in enhancing overall survival in patients with HER2-positive breast cancer. However, some patients exhibit resistance to trast…
Preview only. Read the full abstract at the source